- Home
- ZNTL vs SPXX Comparison
ZNTL vs SPXX Comparison
Compare ZNTL & SPXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ZNTL | SPXX |
|---|---|---|
| Founded | 2014 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 289.0M | 331.3M |
| IPO Year | 2020 | 2005 |
Fundamental Metrics
Financial Performance| Metric | ZNTL | SPXX |
|---|---|---|
| Price | $4.50 | $18.61 |
| Analyst Decision | Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $6.60 | N/A |
| AVG Volume (30 Days) | ★ 1.4M | 285.4K |
| Earning Date | 05-07-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 18.03 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.21 | $15.78 |
| 52 Week High | $6.95 | $18.94 |
Technical Indicators
Market Signals| Indicator | ZNTL | SPXX |
|---|---|---|
| Relative Strength Index (RSI) | 49.87 | 59.09 |
| Support Level | $4.29 | $17.65 |
| Resistance Level | $5.11 | $18.94 |
| Average True Range (ATR) | 0.43 | 0.18 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 16.09 | 71.13 |
Price Performance
Historical ComparisonAbout ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
About SPXX Nuveen S&P 500 Dynamic Overwrite Fund
Nuveen S&P 500 Dynamic Overwrite Fund is a diversified closed-end management investment company. Its investment objective is to seek attractive total returns with less volatility than the S&P 500 Index by investing in a U.S. equity portfolio that seeks to substantially replicate the price movements of the S&P 500 Index, as well as selling call options on approximately 35% to 75% of the notional value of the Fund's equity portfolio in an effort to enhance the Fund's risk-adjusted returns.